Cell culture of neurofibromatosis type 2-associated tumors

Advances in Neurofibromatosis Research

Volumn , Issue , 2012, Pages 181-204

  James, Marianne F ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885019807     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (106)

1. Perry, A.; Gutmann, D.H.; Reifenberger, G. (2004). Molecular pathogenesis of meningiomas. J Neurooncol, 70 (2):183-202.
2. Gutmann, D.H.; Giordano, M.J.; Fishback, A.S.; Guha, A. (1997). Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas. Neurology, 49 (1):267-70.
3. Evans, D.G.; Baser, M.E.; O'Reilly, B.; Rowe, J.; Gleeson, M.; Saeed, S.; King, A.; Huson, S.M.; Kerr, R.; Thomas, N. et al. (2005). Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg, 19 (1):5-12.
4. Trofatter, J.A.; MacCollin, M.M.; Rutter, J.L.; Murrell, J.R.; Duyao, M.P.; Parry, D.M.; Eldridge, R.; Kley, N.; Menon, A.G.; Pulaski, K et al. (1993). A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell, 72 (5):791-800.
5. Rouleau, G.A.; Merel, P.; Lutchman, M.; Sanson, M.; Zucman, J.; Marineau, C.; Hoang-Xuan, K.; Demczuk, S.; Desmaze, C.; Plougastel, B. et al. (1993). Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature, 363:515-21.
6. Ruttledge, M.H.; Sarrazin, J.; Rangaratnam, S.; Phelan, C.M.; Twist, E.; Merel, P.; Delattre, O.; Thomas, G.; Nordenskjold, M.; Collins, V.P. et al. (1994). Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet, 6 (2):180-4.
7. McClatchey, A.I.;Giovannini, M. (2005). Membrane organization and tumorigenesis--the NF2 tumor suppressor, Merlin. Genes Dev, 19 (19):2265-77.
8. Gutmann, D.H.; Haipek, C.A.; Hoang Lu, K. (1999). Neurofibromatosis 2 tumor suppressor protein, merlin, forms two functionally important intramolecular associations. J Neurosci Res, 58 (5):706-16.
9. Lutchman, M.;Rouleau, G.A. (1995). The neurofibromatosis type 2 gene product, schwannomin, suppresses growth of NIH 3T3 cells. Cancer Res, 55 (11):2270-4.
10. Sun, C.X.; Haipek, C.; Scoles, D.R.; Pulst, S.M.; Giovannini, M.; Komada, M.; Gutmann, D.H. (2002). Functional analysis of the relationship between the neurofibromatosis 2 tumor suppressor and its binding partner, hepatocyte growth factor-regulated tyrosine kinase substrate. Hum Mol Genet, 11 (25):3167-78.
11. Xiao, G.H.; Gallagher, R.; Shetler, J.; Skele, K.; Altomare, D.A.; Pestell, R.G.; Jhanwar, S.; Testa, J.R. (2005). The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol Cell Biol, 25 (6):2384-94.
12. Gonzalez-Agosti, C.; Xu, L.; Pinney, D.; Beauchamp, R.; Hobbs, W.; Gusella, J.; Ramesh, V. (1996). The merlin tumor suppressor localizes preferentially in membrane ruffles. Oncogene, 13 (6):1239-47.
13. Pelton, P.D.; Sherman, L.S.; Rizvi, T.A.; Marchionni, M.A.; Wood, P.; Friedman, R.A.; Ratner, N. (1998). Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwannoma cells. Oncogene, 17 (17):2195-209.
14. Hall, A. (1998). Rho GTPases and the actin cytoskeleton. Science, 279 (5350):509-14.
15. Tsukita, S.;Yonemura, S. (1999). Cortical actin organization: lessons from ERM (ezrin/radixin/moesin) proteins. J Biol Chem, 274 (49):34507-10.
16. Morrison, H.; Sherman, L.S.; Legg, J.; Banine, F.; Isacke, C.; Haipek, C.A.; Gutmann, D.H.; Ponta, H.; Herrlich, P. (2001). The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev, 15 (8):968-80.
17. Bretscher, A.; Edwards, K.; Fehon, R.G. (2002). ERM proteins and merlin: integrators at the cell cortex. Nature Reviews Molecular Cell Biology, 3 (8):586-99.
18. Okada, T.; Lopez-Lago, M.; Giancotti, F.G. (2005). Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane. J Cell Biol, 171 (2):361-71.
19. Hamaratoglu, F.; Willecke, M.; Kango-Singh, M.; Nolo, R.; Hyun, E.; Tao, C.; Jafar-Nejad, H.; Halder, G. (2006). The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol, 8 (1):27-36.
20. Scoles, D.R.; Huynh, D.P.; Morcos, P.A.; Coursell, E.R.; Robinson, N.GG.; Tamanoi, F.; Pulst, S.M. (1998). Neurofibromatosis 2 tumor suppressor schwannomin interacts with BII-spectrin. Nat. Genet, 18:354-9.
21. James, M.F.; Han, S.; Polizzano, C.; Plotkin, S.R.; Manning, B.D.; Stemmer-Rachamimov, A.O.; Gusella, J.F.; Ramesh, V. (2009). NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol, 29 (15):4250-61.
22. Lopez-Lago, M.A.; Okada, T.; Murillo, M.M.; Socci, N.; Giancotti, F.G. (2009). Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol Cell Biol, 29 (15):4235-49.
23. McClatchey, A.I.;Cichowski, K. (2001). Mouse models of neurofibromatosis.Biochim Biophys Acta, 1471 (2):M73-80.
24. Gutmann, D.H.;Giovannini M. (2002). Mouse models of neurofibromatosis 1 and 2. Neoplasia, 4 (4):279-90.
25. Kalamarides, M.; Niwa-Kawakita, M.; Leblois, H.; Abramowski, V.; Perricaudet, M.; Janin, A.; Thomas, G.; Gutmann, D.H.; Giovannini, M. (2002). Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes & Development, 16 (9):1060-5.
26. Korf, B.R., Rubenstein, AE. (2005). Neurofibromatosis: A handbook for Patients, Families and Health Care Professionals. 2nd ed. New York: Thieme Medical Publishers.
27. McClatchey, A.I.; Saotome, I.; Mercer, K.; Crowley, D.; Gusella, J.F.; Bronson, R.T.; Jacks, T. (1998). Mice heterozygous for a mutation at the nf2 tumor suppressor locus develop as range of highly metastatic tumors. Genes and Development, 12 (8):1121-33.
28. Giovannini, M.; Robanus-Maandag, E.; Niwa-Kawakita, M.; van der Valk, M.; Woodruff, J.; Goutebroze, L.; Merel, P.; Berns, A.; Thomas, G. (1999). Schwann cell hyperplasia andtumors in transgenic mice expressing a naturally occurring mutant NF2 protein. Genes Dev, 13 (8):978-86.
29. Giovannini, M.; Robanus-Maandag, E.; van der Valk, M.; Niwa-Kawakita, M.; Abramowski, V.; Goutebroze, L.; Woodruff, J.M.; Berns, A.; Thomas, G. (2000). Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev, 14 (13):1617-30.
30. Brockes, J.P.; Fields, K.L.; Raff, M.C. (1979).Studies on cultured rat Schwann cells. I. Establishment of purified populations from cultures of peripheral nerve. Brain Res, 165 (1):105-18.
31. Verdu, E.; Rodriguez, F.J.; Gudino-Cabrera, G.; Nieto-Sampedro, M.; Navarro, X. (2000). Expansion of adult Schwann cells from mouse predegenerated peripheral nerves. J Neurosci Methods, 99 (1-2):111-7.
32. Morrissey, T.K.; Kleitman, N.; Bunge, R.P. (1991). Isolation and functional characterization of Schwann cells derived from adult peripheral nerve. J Neurosci, 11 (8):2433-42.
33. Casella, G.T.; Bunge, R.P.; Wood, P.M. (1996). Improved method for harvesting human Schwann cells from mature peripheral nerve and expansion in vitro. Glia, 17 (4):327-38.
34. Fawcett, J.W, Keynes, R.J. (1990). Peripheral nerve regeneration. Annu Rev Neurosci, 13:43-60.
35. Heumann, R.; Lindholm, D.; Bandtlow, C.; Meyer, M.; Radeke, M.J.; Misko, T.P.; Shooter, E.; Thoenen, H. (1987). Differential regulation of mRNA encoding nerve growth factor and its receptor in rat sciatic nerve during development, degeneration, and regeneration: role of macrophages. Proc Natl Acad Sci U S A, 84 (23):8735-9.
36. Liu, H.M.; Yang, L.H.; Yang, Y.J. (1995). Schwann cell properties: 3. C-fos expression, bFGF production, phagocytosis and proliferation during Wallerian degeneration. J Neuropathol Exp Neurol, 54 (4):487-96.
37. Keilhoff, G.; Fansa, H.; Schneider, W.; Wolf, G. (1999). In vivo predegeneration of peripheral nerves: an effective technique to obtain activated Schwann cells for nerve conduits. J Neurosci Methods, 89 (1):17-24.
38. Corfas, G.; Velardez, M.O.; Ko, C.P.; Ratner, N.; Peles, E. (2004). Mechanisms and roles of axon-Schwann cell interactions. J Neurosci, 24 (42):9250-60.
39. Ratner, N.; Hong, D.M.; Lieberman, M.A.; Bunge, R.P.; Glaser, L. (1998). The neuronal cell-surface molecule mitogenic for Schwann cells is a heparin-binding protein. Proc Natl Acad Sci USA, 85 (18):6992-6.
40. Marchionni, M.A.; Goodearl, A.D.; Chen, M.S.; Bermingham-McDonogh, O.; Kirk, C.; Hendricks, M.; Danehy, F.; Misumi, D.; Sudhalter, J.; Kobayashi, K. et al. (1993). Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. Nature, 362 (6418):312-8.
41. Ratner, N.; Williams, J.P.; Kordich, J.J.; Kim, H.A. (2006). Schwann cell preparation from single mouse embryos: analyses of neurofibromin function in Schwann cells. Methods Enzymol, 407:22-33.
42. Davey, F.;Davies, A.M. (1998). TrkB signalling inhibits p75-mediated apoptosis induced by nerve growth factor in embryonic proprioceptive neurons. Curr Biol, 8 (16):915-8.
43. Davies, A.M. (1998). Neuronal survival: early dependence on Schwann cells. Curr Biol, 8 (1):R15-8.
44. Serra, E.; Rosenbaum, T.; Winner, U.; Aledo, R.; Ars, E.; Estivill, X.; Lenard, H.G.; Lazaro, C. (2000). Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations. Hum Mol Genet, 9 (20):3055-64.
45. Levi, A.D.;Bunge, R.P. (1994). Studies of myelin formation after transplantation of human Schwann cells into the severe combined immunodeficient mouse. Exp Neurol, 130 (1):41-52.
46. Rutkowski, J.L.; Tennekoon, G.I.; McGillicuddy, J.E. (1992). Selective culture of mitotically active human Schwann cells from adult sural nerves. Ann Neurol, 31 (6):580-6.
47. Levi, A.D.; Bunge, R.P.; Lofgren, J.A., Meima, L.; Hefti, F.; Nikolics, K.; Sliwkowski, M.X. (1995). The influence of heregulins on human Schwann cell proliferation. J Neurosci, 15 (2):1329-40.
48. Rutkowski, J.L.; Kirk, C.J.; Lerner, M.A.; Tennekoon, G.I. (1995). Purification and expansion of human Schwann cells in vitro. Nat Med, 1 (1):80-3.
49. Rosenbaum, C.; Kluwe, L.; Mautner, V.; Friedrich, R.; Muller, H.; Hanemann, C. (1998). Isolation and characterization of Schwann cells from neurofibromatosis type 2 patients. Neurobiol Dis, 5:55-64.
50. Hanemann, C.O.; Rosenbaum, C.; Kupfer, S.; Wosch, S.; Stoegbauer, F.; Muller, H.W. (1998). Improved culture methods to expand Schwann cells with altered growth behaviour from CMT1A patients. Glia, 23 (2):89-98.
51. Kim, H.A.; Rosenbaum, T.; Marchionni, M.A.; Ratner, N.; DeClue, J.E. (1995). Schwann cells from neurofibromin deficient mice exhibit activation of p21ras, inhibition of cell proliferation and morphological changes. Oncogene, 11 (2):325-35.
52. Rosenbaum, T.; Rosenbaum, C.; Winner, U.; Muller, H.W.; Lenard, H.G, Hanemann CO. (2000). Long-term culture and characterization of human neurofibroma-derived Schwann cells. J Neurosci Res, 61 (5):524-32.
53. Morrissey, T.K.; Bunge, R.P.; Kleitman, N. (1995). Human Schwann cells in vitro. I. Failure to differentiate and support neuronal health under co-culture conditions that promote full function of rodent cells. J Neurobiol, 28 (2):171-89.
54. Garratt, A.N.; Britsch, S.; Birchmeier, C. (2000). Neuregulin, a factor with many functions in the life of a schwann cell. Bioessays, 22 (11):987-96.
55. Monje, P.V.; Athauda, G.; Wood, P.M. (2008). Protein kinase A-mediated gating of neuregulin-dependent ErbB2-ErbB3 activation underlies the synergistic action of cAMP on Schwann cell proliferation. J Biol Chem, 283 (49):34087-100.
56. Bashour, A.M.; Meng, J.J.; Ip, W.; MacCollin, M.; Ratner, N. (2002). The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells. Mol Cel Biol, 22 (4):1150-7.
57. Deguen, B.; Merel, P.; Goutebroze, L.; Giovannini, M.; Reggio, H.; Arpin, M.; Thomas, G. (1998). Impaired interaction of naturally occurring mutant NF2 protein with actin-basedcytoskeleton and membrane. Hum Mol Genet, 7 (2):217-26.
58. Sherman, L.; Xu, H.M.; Geist, R.T.; Saporito-Irwin, S.; Howells, N.; Ponta, H.; Herrlich, P.; Gutmann DH. (1997). Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene, 15 (20):2505-9.
59. Morgan, L.; Jessen, K.R.; Mirsky, R. (1991). The effects of cAMP on differentiation of cultured Schwann cells: progression from an early phenotype (04+) to a myelin phenotype (P0+, GFAP-, N-CAM-, NGF-receptor-) depends on growth inhibition. J Cell Biol, 112 (3):457-67.
60. Kepes, J.J. (1982). Masson Monographs in Diagnostic Pathology. In: Steinberg, S.S. (ed). Masson Monographs in Diagnostic Pathology. New York: Masson Publishing.
61. Rachlin, J.;Rosenblum, M. Etiology and biology of meningiomas. In: Al-Mefty O (ed). (1991). Meningiomas. New York: Raven Press.
62. Todo, T.; Adams, E.F.; Fahlbusch, R.; Dingermann, T.; Werner, H. (1996). Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor. J Neurosurg, 84 (5):852-8.
63. Humeau, C.; Vic, P.; Sentein, P.; Vlahovitch, B. (1979). The fine structure of meningiomas: an attempted classification. Virchows Arch A Pathol Anat Histol, 382 (2):201-16.
64. Jensen, R.L.; Origitano, T.C.; Lee, Y.S.; Weber, M.; Wurster, R.D. (1995). In vitro growth inhibition of growth factor-stimulated meningioma cells by calcium channel antagonists. Neurosurgery, 36 (2):365-73.
65. Huang, X.;Saint-Jeannet, J.P. (2004). Induction of the neural crest and the opportunities of life on the edge. Dev Biol, 275 (1):1-11.
66. Theaker, J.M.; Gatter, K.C.; Esiri, M.M.; Fleming, K.A. (1986). Epithelial membrane antigen and cytokeratin expression by meningiomas: an immunohistological study. J Clin Pathol, 39 (4):435-9.
67. Frank, E.; Burge, B.; Liwnicz, B.; Lotspeich, L.; White, J.; Wechsler, S.; Mayfield F.; Keller, J. (1983). Cytokeratin provides a specific marker for human arachnoid cell grown in vitro. Exp Cell Res, 146:371-6.
68. O'Rahilly, R.;Muller, F. (1986). The meninges in human development. J Neuropathol Exp Neurol, 45 (5):588-608.
69. Willimas, P.L.; Warwick, W.B. (1975). Functional Neuroanatomy of Man. (Being the neurology section of Gray's Anatomy, 35th ed). Philadelphia: WB Saunders Co.
70. Carpenter, M.B.;Sutin, J. Meninges and the Cerebrospinal Fluid. In: Wilkins, W. (ed). (1983). Human Neuroanatomy. Baltimore: Lippincot.
71. Nolte, J.;Sundsten, J. (2008). The human brain: an introduction to its functional anatomy. 4th ed. St. Louis: Mosby.
72. Bigner, D.D; McLendon, R.E.; Bruner, J.M. (1998). Russell & Rubinstein's Pathology of tumors of the nervous system. 6th ed. Vol. 1 & 2. New York: Oxford University Press.
73. Rutka, J.T.; Giblin, J.; Dougherty, D.V.; McCulloch, J.R.; DeArmond, S.J.; Rosenblum, M.L. (1986). An ultrastructural and immunocytochemical analysis of leptomeningeal and meningioma cultures. J Neuropathol Exp Neurol, 45 (3):285-303.
74. Yamashima, T. (1986). On Arachnoid Villi and Meningiomas: Functional Implication of Ultrastructure, Cell Adhesion Mechanisms, and Extracellular Matrix Composition. Pathol Oncol Res, 2 (3):144-9.
75. Motohashi, O.; Suzuki, M.; Yanai, N.; Umezawa, K.; Shida, N.; Shirane, R.; Yoshimoto, T. (1994). Primary culture of human leptomeningeal cells in serum-free medium. Neurosci Lett, 165 (1-2):122-4.
76. Murphy, M.; Chen, J.N.; George, D.L. (1991). Establishment and characterization of a human leptomeningeal cell line. J Neurosci Res, 30 (3):475-83.
77. Rutka, J.T.; Kleppe-Hoifodt, H.; Emma, D.A.; Giblin, J.R.; Dougherty, D.V.; McCulloch, J.R.; De Armond, S.J.; Rosenblum, M.L. (1986). Characterization of normal human brain cultures. Evidence for the outgrowth of leptomeningeal cells. Lab Invest, 55 (1):71-85.
78. Holman, D.W.; Grzybowski, D.M.; Mehta, B.C.; Katz, S.E.; Lubow, M. (2005). Characterization of cytoskeletal and junctional proteins expressed by cells cultured from human arachnoid granulation tissue. Cerebrospinal Fluid Res, 2:9.
79. Xin, X.; Fan, B.; Killer, H.E.; Neutzner, A.; Flammer, J.; Meyer, P. (2010). Primary cell culture of meningothelial cells-a new model to study the arachnoid in glaucomatous optic neuropathy. Graefes Arch Clin Exp Ophthalmol, 248 (9):1273-8.
80. Yamashima, T.; Kida, S.; Yamamoto, S. (1988). Ultrastructural comparison of arachnoid villi and meningiomas in man. Mod Pathol, 1 (3):224-34.
81. Ng, H.K.; Tse, C.C.; Lo, S.T. (1987).Meningiomas and arachnoid cells: an immunohistochemical study of epithelial markers. Pathology, 19 (3):253-7.
82. Yamashima, T.; Sakuda, K.; Tohma, Y.; Yamashita, J.; Oda, H.; Irikura, D.; Eguchi, N.; Beuckmann, C.T.; Kanaoka, Y.; Urade, Y. et al. (1997). Prostaglandin D synthase (beta-trace) in human arachnoid and meningioma cells: roles as a cell marker or in cerebrospinal fluid absorption, tumorigenesis, and calcification process. J Neurosci, 17 (7):2376-82.
83. Kartenbeck, J.; Schwechheimer, K.; Moll, R.; Franke, W.W. (1984). Attachment of vimentin filaments to desmosomal plaques in human meningiomal cells and arachnoidal tissue. J Cell Biol, 98 (3):1072-81.
84. Schwechheimer, K.; Kartenbeck, J.; Moll, R.; Franke, W.W. (1984). Vimentin filament-desmosome cytoskeleton of diverse types of human meningiomas. A distinctive diagnostic feature. Lab Invest, 51 (5):584-91.
85. Ragel, B.T.; Couldwell, W.T.; Gillespie, D.L.; Wendland, M.M.; Whang, K.; Jensen, R.L. (2008). A comparison of the cell lines used in meningioma research. Surg Neurol, 70 (3):295-307.
86. Campbell, B.A.; Jhamb, A.; Maguire, J.A.; Toyota, B.; Ma, R. (2009). Meningiomas in 2009: controversies and future challenges. Am J Clin Oncol,32 (1):73-85.
87. Gutmann, D.H.; Aylsworth, A.; Carey, J.C.; Korf, B.; Marks, J.; Pyeritz, R.E.; Rubenstein, A.; Viskochil, D. (1997). The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA, 278 (1):51-7.
88. Seizinger, B.R.; de la Monte, S.; Atkins, L.; Gusella, J.F.; Martuza, R.L. (1987). Molecular genetic approach to human meningioma: loss of genes on chromosome 22. Proc Natl Acad Sci U S A, 84 (15):5419-23.
89. Todo, T.; Adams, E.F.; Fahlbusch, R. (1993). Inhibitory effect of trapidil on human meningioma cell proliferation via interruption of autocrine growth stimulation. J Neurosurg, 78 (3):463-9.
90. Pagotto, U.; Arzberger, T.; Hopfner, U.; Sauer, J.; Renner, U.; Newton, C.J.; Lange, M.; Uhl, E.; Weindl, A.; Stalla, G.K. (1995). Expression and localization of endothelin-1 and endothelin receptors in human meningiomas. Evidence for a role in tumoral growth. J Clin Invest, 96 (4):2017-25.
91. Pereda, M.P.; Hopfner, U.; Pagotto, U.; Renner, U.; Uhl, E.; Arzt, E.; Missale, C.; Stalla, GK. (1999). Retinoic acid stimulates meningioma cell adhesion to the extracellular matrix and inhibits invasion. Br J Cancer, 81 (3):381-6.
92. Weisberg, S.; Ashkenazi, E.; Israel, Z.; Attia, M.; Shoshan, Y.; Umansky, F.; Brodie C. (2001). Anaplastic and atypical meningiomas express high levels of Fas and undergo apoptosis in response to Fas ligation. Am J Pathol, 159 (4):1193-7.
93. Adams, E.F.; Todo, T.; Schrell, U.M.; Thierauf, P.; White, M.C.; Fahlbusch, R. (1991). Autocrine control of human meningioma proliferation: secretion of platelet-derived growth-factor-like molecules. Int J Cancer, 49 (3):398-402.
94. Louis, D.N.; Scheithauer, B.W.; Budka, H.; Deimling, V.; Kepes, J.J. Meningiomas. Kleihues, P.; Cavennee, W.K. (eds.). (2000). WHO Classification of tumours. Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC Press.
95. Lamszus, K. Meningioma pathology, genetics, and biology. (2004). J Neuropathol Exp Neurol, 63 (4):275-86.
96. James, M.F, Lelke, J.M.; Maccollin, M.; Plotkin, S.R.; Stemmer-Rachamimov, A.O.; Ramesh, V.; Gusella, J.F. (2008). Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth. Neurobiol Dis, 29 (2):278-92.
97. Murphy, M.; Pykett, M.J.; Harnish, P.; Zang, K.D.; George, D.L. (1993). Identification and characterization of genes differentially expressed in meningiomas. Cell Growth Differ, 4 (9):715-22.
98. Rong, R.; Tang, X.; Gutmann.; D.H.; Ye, K. (2004). Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. Proc Natl Acad Sci U S A, 101 (52):18200-5.
99. Trotter, J. The development of myelin-forming glia: studies with primary cell cultures and immortalized cell lines. (1993). Perspect Dev Neurobiol, 1 (3):149-54.
100. Hung, G.; Li, X.; Faudoa, R.; Xeu, Z.; Kluwe, L.; Rhim, J.S.; Slattery, W.; Lim, D. (2002). Establishment and characterization of a schwannoma cell line from a patient with neurofibromatosis 2. Int J Oncol, 20 (3):475-82.
101. Puttmann, S.; Senner, V.; Braune, S.; Hillmann, B.; Exeler, R.; Rickert, C.H.; Paulus, W. (2005). Establishment of a benign meningioma cell line by hTERT-mediated immortalization. Lab Invest, 85 (9):1163-71.
102. Baia, G.S.; Slocum, A.L.; Hyer, J.D.; Misra, A.; Sehati, N.; VandenBerg, S.R.; Feuerstein, B.G.; Deen, D.F.; McDermott, M.W.; Lal, A. (2006). A genetic strategy to overcome the senescence of primary meningioma cell cultures. J Neurooncol, 78 (2):113-21.
103. Cargioli, T.G.; Ugur, H.C.; Ramakrishna, N.; Chan, J.; Black, P.M.; Carroll, R.S. (2007). Establishment of an in vivo meningioma model with human telomerase reverse transcriptase. Neurosurgery, 60 (4):750-9.
104. Saavedra, J.T.; Wolterman, R.A.; Baas, F.; ten Asbroek, A.L. (2008). Myelination competent conditionally immortalized mouse Schwann cells. J Neurosci Methods, 174 (1):25-30.
105. Techangamsuwan, S.; Kreutzer, R.; Kreutzer, M.; Imbschweiler, I.; Rohn, K.; Wewetzer, K.; Baumgartner, W. (2009). Transfection of adult canine Schwann cells and olfactory ensheathing cells at early and late passage with human TERT differentially affects growth factor responsiveness and in vitro growth. J Neurosci Methods, 176 (2):112-20.
106. Ahmad, Z.; Brown, C.M.; Patel, A.K.; Ryan, A.F.; Ongkeko, R.; Doherty, J.K. (2010). Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis. Otol Neurotol, 31 (3):460-6.